<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01917552</url>
  </required_header>
  <id_info>
    <org_study_id>AMC1301</org_study_id>
    <nct_id>NCT01917552</nct_id>
  </id_info>
  <brief_title>Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer</brief_title>
  <official_title>Phase III Study of Adjuvant Capecitabine vs Observation Alone in Curatively Resected Stage IB (by AJCC 6th Edition) Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Roche Pharma AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      multi-center, prospective, randomized, open-label phase III
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective, randomized, open-label phase III study of adjuvant chemotherapy after
      curative resection in patients with pathologic stage IB (by AJCC 6th edition) gastric cancer
      with at least one additional risk factor (additional risk factors for recurrence include age
      &gt;65 years, male gender, presence of lymphovascular invasion, presence of perineural
      invasion). The superiority design will compare the efficacy and safety profiles of adjuvant
      capecitabine (Arm A) versus observation alone (Arm B).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>recurrence-free survival</measure>
    <time_frame>8 years</time_frame>
    <description>To demonstrate that capecitabine is superior to observation only (control arm) in terms of recurrence-free survival in curatively resected stage IB gastric cancer.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>8 years</time_frame>
    <description>To compare overall survival in the capecitabine arm compared with the control arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profiles</measure>
    <time_frame>8years</time_frame>
    <description>Toxicity profiles will be assessed with the patient 28 +/- 3 days after the last intake of study medication is required. (treatment arm only)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">870</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>capecitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capecitabine 1250 milligram (mg) / m² po bid (D1-14)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
    <description>capecitabine 1250 milligram (mg) / m² po bid (D1-14)</description>
    <arm_group_label>capecitabine</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Curatively resected gastric or gastroesophageal junction adenocarcinoma

          -  Pathologic stage IB (by AJCC 6th edition) with at least one additional risk factor for
             recurrence (additional risk factors for recurrence include age &gt;65 years, male gender,
             presence of lymphovascular invasion, presence of perineural invasion).

          -  Age: 18 -74years

          -  ECOG performance status: 0-2

          -  Adequate bone marrow function (ANC &gt;1,500/uL, Platelets 100,000/uL, and Hb &gt; 8.0 g/dL)

          -  Adequate renal function (serum creatinine &lt; 1.5 mg/dL)

          -  Adequate hepatic function (bilirubin &lt; 1.5 mg/dL, ALT and AST &lt; 3 times upper limit of
             normal)

          -  Written informed consent

        Exclusion Criteria:

          -  Pregnant or lactating women.

          -  Women of childbearing potential with either a positive pregnancy test at baseline.
             Postmenopausal women must have been amenorrheic for at least 12 months to be
             considered of non-child bearing potential.

          -  Sexually active males and females (of childbearing potential) unwilling to practice
             contraception during the study medication and until 3 months after discontinuation of
             the study medication.

          -  Any evidence of metastatic disease (including presence of tumor cells in the ascites).

          -  Previous chemotherapy or radiotherapy for the currently treated gastric cancer.

          -  No recovery from serious complications of gastrectomy.

          -  History of another malignancy within the last five years except cured basal cell
             carcinoma of skin and cured carcinoma in-situ of uterine cervix.

          -  History of uncontrolled seizures, central nervous system disorders or psychiatric
             disability judged by the investigator to be clinically significant precluding informed
             consent or interfering with compliance for oral drug intake.

          -  Clinically significant (i.e. active) cardiac disease: e.g. unstable angina,
             symptomatic coronary artery disease, New York Heart Association (NYHA) grade II or
             greater congestive heart failure or serious cardiac arrhythmia requiring medication or
             myocardial infarction within the last 6 months.

          -  Lack of physical integrity of the upper gastrointestinal tract or those who have
             malabsorption syndrome likely to influence absorption of capecitabine, or inability to
             take oral medication.

          -  Serious uncontrolled intercurrent infections or other serious uncontrolled concomitant
             disease.

          -  Organ allografts requiring immunosuppressive therapy.

          -  Received any investigational drug or agent/procedure, i.e. participation in another
             trial within 4 weeks before randomization.

          -  Requirement for concurrent use of the antiviral agent sorivudine (antiviral) or
             chemically related analogues, such as brivudine.

          -  Positive serologic test for HIV
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kang Yoon-Koo, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kang Yoon-Koo, MD, PhD</last_name>
    <phone>82-2-3010-3230</phone>
    <email>ykkang@amc.seoul.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ryu Min-Hee, MD, PhD</last_name>
    <phone>82-2-3010-5935</phone>
    <email>miniryu@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kang Yoon-Koo, MD, PhD</last_name>
      <phone>82-2-3010-3230</phone>
      <email>ykkang@amc.seoul.kr</email>
    </contact>
    <contact_backup>
      <last_name>Ryu Min-Hee, MD, PhD</last_name>
      <phone>82-2-3010-5935</phone>
      <email>miniryu@amc.seoul.kr</email>
    </contact_backup>
    <investigator>
      <last_name>Kang Yoon-Koo, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryoo Back-Yeol, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ryu Min-Hee, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Park Sook-Ryun, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nam Byung-Ho</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kim Byung-Sik</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yook Jeong-Hwan, MD,PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yoo Moon-Won</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kim Bum-Soo</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <reference>
    <citation>Ajani JA, Faust J, Ikeda K, Yao JC, Anbe H, Carr KL, Houghton M, Urrea P. Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma. J Clin Oncol. 2005 Oct 1;23(28):6957-65. Epub 2005 Sep 6.</citation>
    <PMID>16145066</PMID>
  </reference>
  <reference>
    <citation>Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, Lee KW, Kim YH, Noh SI, Cho JY, Mok YJ, Kim YH, Ji J, Yeh TS, Button P, Sirzén F, Noh SH; CLASSIC trial investigators. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012 Jan 28;379(9813):315-21. doi: 10.1016/S0140-6736(11)61873-4. Epub 2012 Jan 7.</citation>
    <PMID>22226517</PMID>
  </reference>
  <reference>
    <citation>Diasio RB. Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase. Br J Clin Pharmacol. 1998 Jul;46(1):1-4.</citation>
    <PMID>9690942</PMID>
  </reference>
  <reference>
    <citation>Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49. doi: 10.3322/caac.20006. Epub 2009 May 27.</citation>
    <PMID>19474385</PMID>
  </reference>
  <reference>
    <citation>Kang YK, Lee SS, Yoon DH, Lee SY, Chun YJ, Kim MS, Ryu MH, Chang HM, Lee JL, Kim TW. Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study. J Clin Oncol. 2010 Aug 20;28(24):3824-9. doi: 10.1200/JCO.2010.29.1807. Epub 2010 Jul 12.</citation>
    <PMID>20625131</PMID>
  </reference>
  <reference>
    <citation>Kolesar JM, Johnson CL, Freeberg BL, Berlin JD, Schiller JH. Warfarin-5-FU interaction--a consecutive case series. Pharmacotherapy. 1999 Dec;19(12):1445-9.</citation>
    <PMID>10600095</PMID>
  </reference>
  <reference>
    <citation>Lee JL, Kang YK, Kang HJ, Lee KH, Zang DY, Ryoo BY, Kim JG, Park SR, Kang WK, Shin DB, Ryu MH, Chang HM, Kim TW, Baek JH, Min YJ. A randomised multicentre phase II trial of capecitabine vs S-1 as first-line treatment in elderly patients with metastatic or recurrent unresectable gastric cancer. Br J Cancer. 2008 Aug 19;99(4):584-90. doi: 10.1038/sj.bjc.6604536. Epub 2008 Jul 29.</citation>
    <PMID>18665164</PMID>
  </reference>
  <reference>
    <citation>O'Connell MJ, Laurie JA, Kahn M, Fitzgibbons RJ Jr, Erlichman C, Shepherd L, Moertel CG, Kocha WI, Pazdur R, Wieand HS, Rubin J, Vukov AM, Donohue JH, Krook JE, Figueredo A. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol. 1998 Jan;16(1):295-300.</citation>
    <PMID>9440756</PMID>
  </reference>
  <reference>
    <citation>Park JH, Ryu MH, Kim HJ, et al. (2012). Identification of risk factors of relapse after curative surgical resection in stage I gastric cancer. ESMO 2012 annual meeting, abstr number 679.</citation>
  </reference>
  <reference>
    <citation>Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, Furukawa H, Nakajima T, Ohashi Y, Imamura H, Higashino M, Yamamura Y, Kurita A, Arai K; ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007 Nov 1;357(18):1810-20. Erratum in: N Engl J Med. 2008 May 1;358(18):1977.</citation>
    <PMID>17978289</PMID>
  </reference>
  <reference>
    <citation>Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, Nashimoto A, Fujii M, Nakajima T, Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011 Nov 20;29(33):4387-93. doi: 10.1200/JCO.2011.36.5908. Epub 2011 Oct 17.</citation>
    <PMID>22010012</PMID>
  </reference>
  <reference>
    <citation>Lakatos E, Lan KK. A comparison of sample size methods for the logrank statistic. Stat Med. 1992 Jan 30;11(2):179-91.</citation>
    <PMID>1579757</PMID>
  </reference>
  <reference>
    <citation>Collett, D. Modelling Survival Data in Medical Research, Chapman &amp; Hall (1994), Section 9.2</citation>
  </reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 30, 2013</study_first_submitted>
  <study_first_submitted_qc>August 5, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2013</study_first_posted>
  <last_update_submitted>July 13, 2017</last_update_submitted>
  <last_update_submitted_qc>July 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Yoon-Koo Kang</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, adjuvant, capecitabine, gastric cancer, stage 1b</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

